- Home
- VTGN vs AYTU Comparison
VTGN vs AYTU Comparison
Compare VTGN & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | AYTU |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 27.4M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VTGN | AYTU |
|---|---|---|
| Price | $0.66 | $2.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $0.90 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 596.3K | 50.9K |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.43 | $1.46 |
| 52 Week High | $5.14 | $3.07 |
Technical Indicators
Market Signals| Indicator | VTGN | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 34.14 |
| Support Level | $0.63 | $2.15 |
| Resistance Level | $0.65 | $2.30 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 62.68 | 28.91 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.